In 1987, fewer than one in five American adults were obese, and by 1999, obesity was responsible for more than 300,000 excess ...

In the latest trading session, Pfizer (PFE) closed at $26.56, marking a -0.67% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.04%. Elsewhere, the Dow saw ...

Pfizer trades at a 21.7% discount to peers on a 1-yr forward P/E basis, which is a point for the bullish arguments. Find out ...

We recently compiled a list of the 13 Best Dividend Stocks to Buy Under $50. In this article, we are going to take a look at ...

Shares of Pfizer Inc. PFE inched 0.11% higher to $26.74 Tuesday, on what proved to be an all-around great trading session for ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Pfizer yields 6.53% and trades at 9x earnings, while Altria offers 7.58% at 10.1x earnings. Pfizer's troubling 221% payout ...

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a ...

One of Pfizer's recently acquired revenue sources, Padcev, earned approval to treat newly diagnosed bladder cancer patients ...

The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty ...

Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 ...